Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.

@article{Saif2008CorrelationBR,
  title={Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.},
  author={Muhammad Wasif Saif and Walter L. Longo and Gary Israel},
  journal={Clinical colorectal cancer},
  year={2008},
  volume={7 2},
  pages={144-8}
}
Bevacizumab is the fi rst vascular endothelial growth factor-targeted agent shown to increase survival in patients receiving first- and second-line intravenous 5-FU-based chemotherapy for the treatment of metastatic colorectal cancer. Bevacizumab is typically well tolerated and its major side effects include hypertension, proteinuria, bleeding, gastrointestinal perforation and arterial thrombotic events. Although exfoliative dermatitis has been described as a side effect in 19% of patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…